Syncona dives deep into dry AMD R&D, upping Gyroscope bet to $100M
The explosion of gene therapies in the clinic promises to transform the treatment of eye diseases. And Syncona thinks one of their portfolio companies may have found the answer to dry AMD.
The life sciences investment group sunk an additional $57.7 million in Series B funding into the retinal gene therapy group Gyroscope Therapeutics, bringing their total investment to just under $100 million. Syncona maintains an 80% stake in the UK-based outfit. An additional $2.9 million will be provided by Cambridge Innovation Capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.